E
Emmanuel Tsochatzis
Researcher at Royal Free Hospital
Publications - 375
Citations - 13787
Emmanuel Tsochatzis is an academic researcher from Royal Free Hospital. The author has contributed to research in topics: Medicine & Cirrhosis. The author has an hindex of 49, co-authored 302 publications receiving 9698 citations. Previous affiliations of Emmanuel Tsochatzis include Athens State University & University College London.
Papers
More filters
Journal ArticleDOI
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
TL;DR: The 'two-hit' hypothesis is now obsolete, as it is inadequate to explain the several molecular and metabolic changes that take place in NAFLD, and the "multiple hit" hypothesis considers multiple insults acting together on genetically predisposed subjects to induceNAFLD and provides a more accurate explanation of NAFLd pathogenesis.
Journal ArticleDOI
Infections in Patients With Cirrhosis Increase Mortality Four-Fold and Should Be Used in Determining Prognosis
Vasiliki Arvaniti,Gennaro D'Amico,Giuseppe Fede,Pinelopi Manousou,Emmanuel Tsochatzis,M. Pleguezuelo,Andrew K. Burroughs +6 more
TL;DR: In patients with cirrhosis, infections increase mortality 4-fold; 30% of patients die within 1 month after infection and another 30% die by 1 year; prospects with prolonged follow-up evaluation and to evaluate preventative strategies are needed.
Journal ArticleDOI
Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy
Emmanuel Tsochatzis,Kurinchi Selvan Gurusamy,S. Ntaoula,Evangelos Cholongitas,Brian R. Davidson,A.K. Burroughs +5 more
TL;DR: Elastography theoretically has good sensitivity and specificity for cirrhosis (and less for lesser degrees of fibrosis); however, it should be cautiously applied to everyday clinical practice because there is no validation of the stiffness cut-offs for the various stages.
JournalDOI
Glucocorticosteroids for people with alcoholic hepatitis (Protocol)
Journal ArticleDOI
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Philip N. Newsome,Philip N. Newsome,Magali Sasso,Jonathan J Deeks,Jonathan J Deeks,Angelo H. Paredes,Jérôme Boursier,Wah-Kheong Chan,Yusuf Yilmaz,Sébastien Czernichow,Ming-Hua Zheng,Ming-Hua Zheng,Vincent Wai-Sun Wong,Michael Allison,Emmanuel Tsochatzis,Quentin M. Anstee,David Sheridan,Peter J Eddowes,Indra Neil Guha,Jeremy F. L. Cobbold,Valérie Paradis,Pierre Bedossa,Véronique Miette,Céline Fournier-Poizat,Laurent Sandrin,Stephen A. Harrison +25 more
TL;DR: The FAST score provides an efficient way to non-invasively identify patients at risk of progressive NASH for clinical trials or treatments when they become available, and thereby reduce unnecessary liver biopsy in patients unlikely to have significant disease.